Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Laura F. Hutchins' research focuses on cancer care, treatment outcomes, and health disparities. She has investigated the consistency of cancer registry data with all-payer claims databases, particularly concerning radiation therapy among breast cancer patients who have undergone conservative surgery. Her work also examines racial disparities in adherence to endocrine therapy for women diagnosed with early-stage, hormone receptor-positive breast cancer, utilizing data from the Arkansas All-Payers Claims Database.
In addition to breast cancer, Hutchins has analyzed immune adverse events associated with adjuvant ipilimumab in melanoma treatment and the use of immunosuppressants in relation to patient outcomes, drawing on data from the ECOG-ACRIN E1609 study. She has also contributed to assessments of the status of cancer care at academic cancer centers nationwide. Hutchins is a highly cited researcher with 153 publications and a h-index of 44. She leads a research group at the University of Arkansas for Medical Sciences and collaborates with researchers such as Sindhu Janarthanam Malapati and Chenghui Li.
Metrics
- h-index: 44
- Publications: 153
- Citations: 9,676
Selected Publications
-
Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database (2024)
-
Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery (2023)
-
Reporting consistency in radiation therapy after breast conservative surgery between Arkansas Cancer Registry and all payers claims database. (2022)
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis (2021)
Collaboration Network
Top Collaborators
- Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery
- Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database
- Reporting consistency in radiation therapy after breast conservative surgery between Arkansas Cancer Registry and all payers claims database.
- Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery
- Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database
- Reporting consistency in radiation therapy after breast conservative surgery between Arkansas Cancer Registry and all payers claims database.
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Status of Cancer Care at Network Sites of the Nation’s Academic Cancer Centers
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Similar Researchers
Based on overlapping research topics